AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • March 16th, 2023 • Immunome Inc. • Pharmaceutical preparations
AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment #3”) dated as of December 30, 2022 between Immunome, Inc. (the “Company”) and Arrayjet Limited (the “Arrayjet”).
MASTER SERVICES AGREEMENTMaster Services Agreement • March 16th, 2023 • Immunome Inc. • Pharmaceutical preparations
THIS MASTER SERVICES AGREEMENT is made as of this 8th day of November, 2016 (the “Effective Date”) by and between Arrayjet Limited, a company incorporated under the Companies Acts in Scotland, UK [***], and its affiliates, (“Arrayjet”) and Immunome, Inc., a Delaware corporation with an address at 3001 Market Street, Suite 140, Philadelphia, PA 19104 (“Immunome”).
ContractImmunome Inc. • March 16th, 2023 • Pharmaceutical preparations
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IMMUNOME, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO IMMUNOME, INC. IF PUBLICLY DISCLOSED.
AMENDMENT #2 TO MASTER SERVICES AGREEMENTMaster Services Agreement • March 16th, 2023 • Immunome Inc. • Pharmaceutical preparations
AMENDMENT #2 TO MASTER SERVICES AGREEMENT (this “Amendment”) dated as of January 1, 2022 between Immunome, Inc. (“Immunome”) and Arrayjet Limited (“Arrayjet”). Capitalized terms not herein defined have the meaning assigned to them in the Agreement.
AMENDMENT #3 TO MASTER SERVICES AGREEMENTMaster Services Agreement • March 16th, 2023 • Immunome Inc. • Pharmaceutical preparations
AMENDMENT #3 TO MASTER SERVICES AGREEMENT (this “Amendment”) dated as of December 30, 2022 between Immunome, Inc. (“Immunome”) and Arrayjet Limited (“Arrayjet”). Capitalized terms not herein defined have the meaning assigned to them in the Agreement (as defined below).
